• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Peterson Capital Hosts Canada Growth Conference in Ireland

    9/25/25 2:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email

    DUBLIN, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Seven of Canada's fastest growing public companies will be gathering outside of Dublin today as they kick off the third Canada Growth Conference hosted by Edmonton-based capital markets advisory firm Peterson Capital.

    More than fifty public company CEOs, Investment Advisors, fund managers and family offices will meet at the Powerscourt Hotel Resort from Thursday evening, September 25th to Saturday noon, September 27th  for presentations, informal receptions, meetings and social gatherings designed to highlight the opportunities that each of the public companies offers to potential investors.

    "We've held two conferences with the exact same format as this one in Montreal last May and in France in 2022," said Greg Stumph, Peterson Capital's President & COO, "and the feedback from everyone was extremely positive.

    "We have an extremely impressive group of attendees here again – both from our clients and the investor guests - and we're encouraging them to spend time getting to know each other and establish connections that will last beyond the conference. Aside from the presentations, we're also having fun on Saturday with our seven CEOs by putting each of them through a ‘Bear Pit' session and really getting to learn more about each of them. That was extremely popular in Montreal and we're expecting it to be a highlight again here this weekend."

    • The seven companies presenting are Peterson Capital clients Eupraxia Pharmaceuticals (NASDAQ:EPRX) (TSX:EPRX), Logan Energy (LGN.V), Wesdome Gold Mines Ltd. (TSX:WDO, OTCQX:WDOFF) , Colonial Coal International Corp. (TSXV:CAD), Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB), PowerWood Canada and Hypercharge Networks Corp. (TSXV:HC) (OTCQB:HCNWF) (FSE: PB7).

    Conference attendees will vote on Saturday at noon on the company that they feel was the top growth story of the conference. The winner will take home the Canada Growth Cup, which was awarded to Eupraxia Pharmaceuticals in Montreal last May and to Volatus Aerospace at the inaugural Canada Growth Conference in the south of France in 2022.

    "Interest in Canadian growth stories has never been higher," said Peterson Capital founder Rick Peterson, "and this event is a testament to that. Attendance numbers are the highest we've seen in our three conferences. The Embassy of Canada to Ireland based in Dublin will be there and our keynote speaker at lunch on Friday will be Richard McGrath, Executive Director and Head of Investment of AGF International Advisors in Dublin."

    About Peterson Capital:

    Peterson Capital is a capital markets advisory firm founded in 2003 with its head office is in Edmonton and regional offices from coast-to-coast across Canada as well as into Europe and the UK. The company provides introductory services to a network of Investment Advisors, fund managers and family office CEOs with access to more than $15 billion in discretionary investment capital.

    For more information, please contact Greg Stumph at [email protected].



    Primary Logo

    Get the next $EPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    3/23/2026Outperform
    William Blair
    7/24/2025$11.00Overweight
    Cantor Fitzgerald
    6/26/2025$12.00Buy
    H.C. Wainwright
    6/16/2025Speculative Buy
    Canaccord Genuity
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Eupraxia Pharmaceuticals

    William Blair initiated coverage of Eupraxia Pharmaceuticals with a rating of Outperform

    3/23/26 8:28:50 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    7/24/25 7:27:25 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    H.C. Wainwright initiated coverage on Eupraxia Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/26/25 8:10:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

    For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study.Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline (as measured by SDI, where a 3 point reduction is clinical remission).Across dose cohorts 4-9, the decrease in symptom response is the highest at 24 weeks, compared to earlier timepoints. This underlines the value of continuous and steady steroid exposure to reduce infl

    3/17/26 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

    VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2025. All dollar values are in U.S. dollars unless stated otherwise. "2025 was a pivotal year for Eupraxia. We achieved significant clinical milestones in the development of our lead program, EP-104GI, and strengthened our balance sheet with two recent financings, positioning us well for our ne

    3/12/26 9:03:47 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

    VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, is pleased to announce the successful closing of its previously announced public offering (the "Offering") of 7,607,145 common shares of the Company (the "Common Shares"), which includes the full exercise of the option to purchase additional shares granted to the underwriters, at a price to the public of US$7.00 per Common Share, and pre-funded warrants to pu

    2/20/26 3:10:55 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    SEC Filings

    View All

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    3/17/26 7:00:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 40-F filed by Eupraxia Pharmaceuticals Inc.

    40-F - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    3/12/26 9:18:38 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    3/6/26 1:57:41 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

    SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/7/24 4:10:15 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eupraxia Pharmaceuticals Announces CFO Succession

    -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

    2/18/25 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

    VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

    10/31/24 7:36:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Financials

    Live finance-specific insights

    View All

    Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis ("EoE")Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025 VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with

    8/12/25 4:25:54 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

    Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

    5/6/25 6:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

    VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

    3/20/25 5:30:48 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care